Zeta Global Reports Strong FY2025 Results with Revenue Growth, Operating Profitability, and Active Share Repurchase

summarizeSummary

Zeta Global Holdings Corp.'s 2025 Annual Report on Form 10-K provides a comprehensive and highly positive update on the company's financial health and strategic execution. The report confirms a significant turnaround, moving from an operating loss in 2024 to operating profitability in 2025, alongside robust revenue growth and strong customer retention. The successful integration of the Marigold acquisition and the substantial share repurchase program demonstrate effective capital allocation and management confidence. While legal proceedings remain an ongoing risk, the overall financial performance and strategic progress reinforce a strong growth trajectory for the company.

check_boxKey Events

• Strong Financial Performance

  Zeta Global achieved 29.7% revenue growth, reaching $1.3 billion for the full year 2025, and successfully transitioned from an operating loss of $67.9 million in 2024 to an operating income of $5.4 million in 2025.

• Improved Profitability Metrics

  Adjusted EBITDA increased by 44.4% to $278.7 million in 2025, with an improved margin of 21.4%. The net loss was significantly reduced from $69.8 million in 2024 to $31.5 million in 2025.

• Robust Customer Growth and Retention

  The company grew its super-scaled customer base (customers generating over $1 million in revenue) by 24% to 184, with an 8% increase in average revenue per user (ARPU) to $6.2 million, and a strong net revenue retention (NRR) rate of 128.0%.

• Strategic Acquisition Completed

  Zeta Global completed the acquisition of Marigold's Enterprise Business on November 24, 2025, for an aggregate purchase consideration of $302.8 million, including $92.0 million in Class A common stock, expanding its market presence and capabilities.

auto_awesomeAnalysis

Zeta Global Holdings Corp.'s 2025 Annual Report on Form 10-K provides a comprehensive and highly positive update on the company's financial health and strategic execution. The report confirms a significant turnaround, moving from an operating loss in 2024 to operating profitability in 2025, alongside robust revenue growth and strong customer retention. The successful integration of the Marigold acquisition and the substantial share repurchase program demonstrate effective capital allocation and management confidence. While legal proceedings remain an ongoing risk, the overall financial performance and strategic progress reinforce a strong growth trajectory for the company.